[1]
Jeesa George, “Pharmacovigilance During Pre-Approval Phases -Comparison of ICH E2E, CIOMS VI, FDA, EMEA/CHMP and CDSCO Risk Management Guidelines”, IJPRSE, vol. 3, no. 07, pp. 80–86, Jul. 2022.